Work

Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics

Year: 2026

Type: article

Study design: Observational Study

Abstract: Among underserved people with HIV with a median of one year of long-acting cabotegravir-rilpivirine use, including those starting with viremia due to adherence challenges, we found higher satisfaction and lower treatment burden compared to daily oral ART, although nearly half preferred another dosing modality and/or a longer dosing interval.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofag559

Authors: Katerina A Christopoulos, Alex Beckert, Caleb McCracken, Kaylin Dance, Sophie Plotkin, Lauren F Collins, Moira C McNulty, Matthew D Hickey, Mallory O Johnson, Aaloke Mody, Xavier A Erguera, Kimberly A Koester, Geoffroy Liegeon, Jorge Salazar, Jose Gutierrez, Janet Grochowski, Samantha E Dilworth, Torsten B Neilands, Elizabeth T Montgomery, Jonathan A Colasanti

Institutions: University of California, San Francisco, University of Illinois Chicago, Washington University in St. Louis, Emory University, Grady Health System, University of Chicago, Assistance Publique – Hôpitaux de Paris, Hôpital Lariboisière, Hôpital Saint-Louis, RTI International

Language: English

Topic: HIV/AIDS Research and Interventions

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053

Funders: National Institutes of Health, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases

Awards: G7795561155, G9000370577

OpenAlex ID: W7213611823

FWCI:

Cites: 15

Cited by:

Related to: